Comment on the Recommendation of the German Society of Cytology for Primary Screening for Human Papilloma Viruses in Prevention of Cervical Cancer;Kommentar zur Stellungnahme der Deutschen Gesellschaft für Zytologie zum Primären Screening auf Humane Papillomviren im Rahmen der Gynäkologischen Krebsfrüherkennung

Geburtshilfe und Frauenheilkunde

Volumn 64, Issue 1, 2004, Pages 25-26

  Schneider, Achim ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER CYTODIAGNOSIS; CANCER PREVENTION; CANCER SCREENING; COST BENEFIT ANALYSIS; FEMALE; GERMANY; HIGH RISK POPULATION; HUMAN; HUMAN CELL; MEDICAL SOCIETY; NOTE; PRACTICE GUIDELINE; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; VIRUS INFECTION; WART VIRUS;

EID: 1642512390     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2003-44693     Document Type: Note

References (4)

1. Mandelblatt JS, Lawrence WF, Womack SM, Jacobson D, Yi B, Hwang YT, Gold K, Barter J, Shah K. Benefits and costs of using HPV testing to screen for cervical cancer. JAMA 2002; 287: 2372-2381
2. Petry KU, Menton S, Menton M, van Loenen-Frosch F, de Carvalho Gomes H, Holz B, Schopp B, Garbrecht-Buettner S, Davies P, Boehmer G, van den Akker E, Ikner T. Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patients. Br J Cancer 2003; 88: 1570-1577
3. Schneider A, Hoyer H, Lotz B, Leistritz S, Kühne-Heid R, Nindl I, Härting J, Dürst M. Screening for high grade cervical intraepithelial neoplasia and cancer by testing for high risk HPV, routine cytology or colposcopy. Int J Cancer 2000; 89: 529-534
4. Ulsenheimer K. Arztstrafrecht in der Praxis. 2. Aufl. Heidelberg: C. F. Müller, 1998: 79ff und persönliche Mitteilung